2H51.F Ocugen Inc
- Market cap
- EUR 299M
- P/E
- -
- P/B
- 75.99x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 2H51.F undervalued?
Graham numberThe Graham number of Ocugen Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ocugen Inc fundamental analysis
No fundamental analysis for Ocugen Inc yet.
Ocugen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the…
Full company profileOcugen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ocugen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 42.6K | 42.6K | -380.00 | 2.49M | 6.04M | 4.06M | 4.41M | 6.63M |
| Operating Income | -25.0M | -25.8M | -14.2M | -21.3M | -58.0M | -84.9M | -65.5M | -54.8M | -62.9M | -69.4M |
| EBITDA | -23.4M | -25.4M | -18.4M | -21.0M | -58.3M | -88.6M | -64.8M | -51.4M | -60.3M | -49.4M |
| Net Income | -26.4M | -8.64M | -20.2M | -21.8M | -58.4M | -81.4M | -63.1M | -54.1M | -67.8M | -63.5M |
| EPS | -64 | -8.36 | -0.38 | -0.12 | -0.29 | -0.37 | -0.25 | -0.19 | -0.22 | -0.19 |
| Balance Sheet | ||||||||||
| Total Assets | 11.0M | 17.4M | 16.8M | 27.4M | 106M | 109M | 64.5M | 82.4M | 43.5M | 108M |
| Total Liabilities | 22.3M | 17.9M | 5.79M | 5.83M | 9.94M | 24.6M | 24.0M | 52.8M | 55.7M | 126M |
| Shareholders' Equity | -11.3M | -458K | 11.0M | 21.6M | 95.8M | 84.1M | 40.6M | 29.6M | -12.2M | -17.7M |
| Cash & Short-term Investments | 7.08M | 15.5M | 7.44M | 24.0M | 95.0M | 77.6M | 39.5M | 58.5M | 18.6M | 24.6M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -6.32M | -11.6M | -16.9M | -14.7M | -47.9M | -60.1M | -62.1M | -42.1M | -57.0M | -66.3M |
| Capital Expenditure | 170K | 77.4K | 30.0K | 307K | 1.07M | 4.46M | 10.5M | 3.39M | 185K | 235K |
| Free Cash Flow | -23.3M | -17.8M | -16.9M | -15.0M | -48.9M | -64.5M | -72.5M | -45.5M | -57.1M | -66.5M |
| Ratios | ||||||||||
| ROE | - | - | -183.7% | -101.3% | -60.9% | -96.8% | -155.5% | -182.4% | - | - |
| ROA | -239.4% | -49.6% | -120.4% | -79.7% | -55.2% | -74.9% | -97.7% | -65.6% | -155.9% | -58.8% |
| Net Profit Margin | - | - | -47,495.6% | -51,201.2% | - | -3,269.7% | -1,045.0% | -1,333.0% | -1,537.4% | -958.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ocugen Inc dividends
Ocugen Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:60 on Oct 1, 2019.
Who owns Ocugen Inc
- Insiders 1.40%
- Institutions 45.00%
- Public & others 53.60%
- Shares outstanding 339M
- Free float 334M
Ocugen Inc company profile
- Company name
- Ocugen Inc
- Ticker
- 2H51.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 116
- Fiscal year end
- December
- Address
- 11 Great Valley Parkway, Malvern, PA, United States, 19355
- Phone
- 484 328 4701
- Website
- ocugen.com
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Ocugen Inc management
10- Dr. Shankar Musunuri M.B.A., Ph.D.Co-Founder, CEO & Chairman · born 1964
- Dr. Arun Upadhyay Ph.D.Chief Scientific Officer and Head of Research & Development · born 1982
- Ms. Rita Johnson-Greene M.B.A.CFO & Principal Accounting Officer · born 1977
- Mr. Paul StaidExecutive Vice President of Operations
- John Kouch J.D.General Counsel
- Mr. Chris ClarkVP of Corporate Communications
- Ms. Kristen CraftHead of People & Culture
- Dr. Vijay Tammara Ph.D.Chief Development Officer · born 1960
- Dr. Mohamed Genead M.D., M.Sc.Chief Medical Officer
- Ms. Jyothy Pillai M.S.VP & Head of Regulatory & Quality